An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and Co-administration of CKD-501, D744 and D150 for Healthy Adult Volunteers in Fasting State
Latest Information Update: 30 Dec 2025
At a glance
- Drugs Lobeglitazone (Primary) ; Lobeglitazone/D745/D150-Chong-Kun-Dang (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 30 Dec 2025 New trial record